Publications by authors named "Jeff Whittle"

The Veterans Health Administration (VHA) provides maternity care by paying for Veterans to receive pregnancy-related care in community settings and by utilizing maternity care coordinators (MCCs) at each medical facility. The purpose of this qualitative descriptive study was to understand the MCC's experiences performing their role across VA facilities. Thirty MCCs were recruited and interviewed virtually using Microsoft Teams.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess the effectiveness and safety of low (81 mg) versus high-dose (325 mg) aspirin in patients with established atherosclerotic cardiovascular disease (ASCVD) across different racial groups.
  • Conducted as a secondary analysis of the ADAPTABLE trial, the research involved over 14,000 participants from various racial backgrounds and compared their responses to different aspirin doses over a median follow-up of 26.2 months.
  • The results indicated that race did not significantly alter the effectiveness or safety of aspirin dosing, suggesting that all racial groups responded similarly to the treatment.
View Article and Find Full Text PDF

Prior research on racial/ethnic disparities in COVID-19 mortality has often not considered to what extent they reflect COVID-19-specific factors, versus preexisting health differences. This study examines how racial/ethnic disparities in COVID-19 mortality vary with age, sex, and time period over April-December 2020 in the United States, using mortality from other natural causes as a proxy for underlying health. We study a novel measure, the COVID excess mortality percentage (CEMP), defined as the COVID-19 mortality rate divided by the non-COVID natural mortality rate, converted to a percentage, where the CEMP denominator controls (albeit imperfectly) for differences in population health.

View Article and Find Full Text PDF
Article Synopsis
  • In patients with atherosclerotic cardiovascular disease, increased age is linked to higher risks of both ischemic and bleeding events, prompting a study on the effect of aspirin dosage based on age.
  • The ADAPTABLE trial involved nearly 15,100 participants who were randomly assigned to take either 81 mg or 325 mg of aspirin daily, with outcomes measured over an average follow-up of 26.2 months.
  • Results indicated that age did not significantly affect how aspirin dosage influenced clinical outcomes, suggesting that both doses are similarly effective for elderly and younger patients in preventing cardiovascular events.
View Article and Find Full Text PDF

COVID-19 mortality rates increase rapidly with age, are higher among men than women, and vary across racial/ethnic groups, but this is also true for other natural causes of death. Prior research on COVID-19 mortality rates and racial/ethnic disparities in those rates has not considered to what extent disparities reflect COVID-19-specific factors, versus preexisting health differences. This study examines both questions.

View Article and Find Full Text PDF
Article Synopsis
  • Patients with diabetes mellitus (DM) and atherosclerotic cardiovascular disease (ASCVD) were studied to determine the impact of different aspirin doses on cardiovascular risks and bleeding events.* -
  • The research involved 15,076 patients, revealing that those with DM had higher rates of cardiovascular issues and bleeding compared to those without DM, regardless of whether they took 81 mg or 325 mg of aspirin.* -
  • The results indicate that increasing the dose of aspirin does not provide additional benefits for patients with DM, highlighting their increased risk in general rather than a response to medication.*
View Article and Find Full Text PDF

Importance: Guidelines recommend shared decision-making prior to initiating lung cancer screening (LCS). However, evidence is lacking on how to best implement shared decision-making in clinical practice.

Objective: To evaluate the impact of an LCS Decision Tool (LCSDecTool) on the quality of decision-making and LCS uptake.

View Article and Find Full Text PDF
Article Synopsis
  • Internet-based participation in clinical trials can improve diversity and relevance, but there are key differences between internet and noninternet participants, particularly in demographics and health status.
  • In the ADAPTABLE study, noninternet participants were generally older, more likely to be female, and had higher rates of comorbid conditions, resulting in poorer health outcomes compared to internet participants.
  • Noninternet participants also exhibited greater issues with medication adherence, suggesting that while noninternet options can enhance diversity in trials, strategies are needed to improve their retention and adherence rates.
View Article and Find Full Text PDF
Article Synopsis
  • - The ADAPTABLE trial examined the effects of different doses of aspirin (81 mg vs 325 mg daily) on cardiovascular events and bleeding rates in patients with existing cardiovascular disease, finding no significant differences between the two doses.
  • - In a secondary analysis focusing on patients with chronic kidney disease (CKD), results showed that CKD patients had a higher risk of adverse cardiovascular outcomes and major bleeding, regardless of the aspirin dose they were taking.
  • - The study concluded that while CKD increased the risk for complications, the dosing of aspirin did not affect the risk of adverse events or bleeding in these patients.
View Article and Find Full Text PDF

Prior research generally finds that the Pfizer-BioNTech (BNT162b2) and Moderna (mRNA1273) COVID-19 vaccines provide similar protection against mortality, sometimes with a Moderna advantage due to slower waning. However, most comparisons do not address selection effects for those who are vaccinated and with which vaccine. We report evidence on large selection effects, and use a novel method to control for these effects.

View Article and Find Full Text PDF
Article Synopsis
  • A study explored how different doses of aspirin (81 mg vs 325 mg) affected health outcomes in patients with peripheral artery disease (PAD) and examined their involvement in a clinical trial.
  • Results indicated that participants with PAD experienced significantly higher rates of serious health events like heart attacks and strokes, but higher aspirin doses did not offer any additional benefits.
  • Additionally, patients with PAD showed lower rates of enrollment and internet engagement in the study, highlighting the need for tailored research and strategies to better involve these patients in clinical trials.
View Article and Find Full Text PDF

COVID-19 vaccines have saved millions of lives; however, understanding the long-term effectiveness of these vaccines is imperative to developing recommendations for booster doses and other precautions. Comparisons of mortality rates between more and less vaccinated groups may be misleading due to selection bias, as these groups may differ in underlying health status. We studied all adult deaths during the period of 1 April 2021-30 June 2022 in Milwaukee County, Wisconsin, linked to vaccination records, and we used mortality from other natural causes to proxy for underlying health.

View Article and Find Full Text PDF

The integration of motivational strategies and self-management theory with mHealth tools is a promising approach to changing the behavior of patients with chronic disease. In this manuscript, we describe the development and current architecture of a prototype voice-activated self-monitoring application (VoiS) which is based on these theories. Unlike prior mHealth applications which require textual input, VoiS app relies on the more convenient and adaptable approach of asking users to verbally input markers of diabetes and hypertension control through a smart speaker.

View Article and Find Full Text PDF

COVID-19 vaccines have saved millions of lives and prevented countless adverse patient disease outcomes. Understanding the long-term effectiveness of these vaccines is imperative to developing recommendations for precautions and booster doses. Comparisons between more and less vaccinated groups may be misleading due to selection bias, as these groups may differ in underlying health status and thus risk of adverse COVID-19 outcomes.

View Article and Find Full Text PDF

The COVID-19 pandemic has disproportionately affected the elderly. This Article provides a detailed analysis of those effects, drawing primarily on individual-level mortality data covering almost three million persons aged 65+ in three Midwest states (Indiana, Illinois, and Wisconsin). We report sometimes surprising findings on population fatality rates ("PFR"), the ratio of COVID to non-COVID deaths, reported as a percentage, which we call the "Covid Mortality Percentage," and mean life expectancy loss ("LEL").

View Article and Find Full Text PDF

Background: The SPRINT (Systolic Blood Pressure Intervention Trial) demonstrated reductions in major cardiovascular disease events and mortality with an intensive systolic blood pressure (SBP) goal intervention. However, a detailed description of the blood pressure intervention, antihypertensive medication usage, blood pressure levels, and rates and predictors of blood pressure control has not been reported previously.

Methods: Hypertensive participants (n=9361) 50 years and older with elevated cardiovascular disease risk were randomized 1:1 to SBP goal <120 mm Hg or SBP goal <140 mm Hg.

View Article and Find Full Text PDF

Background: Web-based tools developed to facilitate a shared decision-making (SDM) process may facilitate the implementation of lung cancer screening (LCS), an evidence-based intervention to improve cancer outcomes. Veterans have specific risk factors and shared experiences that affect the benefits and potential harms of LCS and thus may value a veteran-centric LCS decision tool (LCSDecTool).

Objective: This study aims to conduct usability testing of an LCSDecTool designed for veterans receiving care at a Veteran Affairs medical center.

View Article and Find Full Text PDF

With 20 million living veterans and millions more immediate family members, and approximately 9 million veterans enrolled in the nationally networked VA healthcare system, representing the interests and needs of veterans in this complex community is a substantial endeavor. Based on the importance of engaging Veterans in research, the VA Health Services Research and Development (HSR&D) Service convened a Working Group of VA researchers and Veterans to conduct a review of patient engagement models and develop recommendations for an approach to engage Veterans in health research that would incorporate their unique lived experiences and interests, and their perspectives on research priorities. The Working Group considered the specific context for Veteran engagement in research that includes other VA stakeholders from the operational and clinical leadership of the VA Health Administration (VHA).

View Article and Find Full Text PDF

Background: Patient engagement in research agenda setting is increasingly being seen as a strategy to improve the responsiveness of healthcare to patient priorities. Implementation of low-dose computed tomography (LDCT) screening for lung cancer is suboptimal, suggesting that research is needed.

Objectives: This study aimed to describe an approach by which a Veteran patient group worked with other stakeholders to develop a research agenda for LDCT screening and to describe the research questions that they prioritized.

View Article and Find Full Text PDF

Background: The public health crises that emerged in the COVID-19 pandemic significantly impacted the provision of medical care and placed sudden restrictions on ongoing clinical research. Patient-facing clinical research confronted unique challenges in which recruitment and study protocols were halted and then adapted to meet safety procedures during the pandemic. Our study protocol included the use of a Lung Cancer Screening Decision Tool (LCSDecTool) in the context of a primary care visit and was considerably impacted by the pandemic.

View Article and Find Full Text PDF

Background: The appropriate dose of aspirin to lower the risk of death, myocardial infarction, and stroke and to minimize major bleeding in patients with established atherosclerotic cardiovascular disease is a subject of controversy.

Methods: Using an open-label, pragmatic design, we randomly assigned patients with established atherosclerotic cardiovascular disease to a strategy of 81 mg or 325 mg of aspirin per day. The primary effectiveness outcome was a composite of death from any cause, hospitalization for myocardial infarction, or hospitalization for stroke, assessed in a time-to-event analysis.

View Article and Find Full Text PDF

For the past 4 years, as part of the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) grant award number UL1TR001436, the Clinical Translational Science Institute of Southeast Wisconsin (CTSI) has used process engineering approaches to identify and understand barriers that local researchers and other stakeholders face when engaging in clinical and translational science. We describe these approaches and present preliminary results. We identified barriers from published and unpublished work at other CTSA hubs, supplemented by surveys and semi-structured interviews of CTSI faculty.

View Article and Find Full Text PDF

Background: Cognitive activity in early and late life has been associated with increased cognitive function among older adults. There is less evidence on the effects of midlife cognitive activity.

Aims: We examined the association of midlife cognitive activity with cognitive function after age 65.

View Article and Find Full Text PDF

Background: Results from the Systolic Blood Pressure Intervention Trial (SPRINT) showed that intensive control of systolic blood pressure significantly reduced the occurrence of mild cognitive impairment, but not probable dementia. We investigated the effects of intensive lowering of systolic blood pressure on specific cognitive functions in a preplanned substudy of participants from SPRINT.

Methods: SPRINT was an open-label, multicentre, randomised controlled trial undertaken at 102 sites, including academic medical centres, Veterans Affairs medical centres, hospitals, and independent clinics, in the USA and Puerto Rico.

View Article and Find Full Text PDF